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Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard therapy in many settings,
with “real world” patients under-represented in clinical trials and prognostic models. Here, using a case-based format, we illustrate
the impact that socioeconomic and anthropogeographical constraints can have on optimally managing AML in 4 different
healthcare systems. The granular details provided, emphasize the need for the development and targeting of socioeconomic
interventions that are commensurate with the changing landscape of AML therapeutics, in order to avoid worsening the disparity in
outcomes between patients with biologically similar disease.
Blood Cancer Journal (2021)11:141 ; https://doi.org/10.1038/s41408-021-00533-0

INTRODUCTION
Until relatively recently, the drug therapy of non-promyelocytic
acute myeloid leukemia (AML) had remained unchanged for over
40 years [1, 2]. An improved understanding of the molecular
heterogeneity of AML [3, 4], recognition of disease with
“actionable” targets [5] and the development of enhanced drugdelivery systems [6] are now yielding novel pharmacological
approaches to treatment. As monotherapy, the effectiveness of
these drugs is mostly restricted to modest increments in disease
control [7–9], but when positioned appropriately with existing
treatments, including stem cell transplantation, a clinically meaningful improvement in outcomes appears to be emerging
[6, 10, 11]. The treatment paradigm for AML thus continues to
evolve, informed by therapeutic intervention relevant to disease
biology [12, 13] and in clinical trials aiming to standardize
prognostication and, measurable residual disease (MRD) assessment, risk-adapt treatments, and improve survival [14].
Amidst this optimism, there remains a need to be cognizant of
the many non-biological factors (NBF) unrelated to AML [15, 16] that
could make the delivery of advances to many patients challenging.
NBF include variations in levels of socioeconomic development,
education, access to services, alcohol addiction, and mental health,
which combined with the sustainability of funding within healthcare
systems, can become the bottleneck that determines the equity of
healthcare for AML patients. The detrimental impact of some of
these variables is exempliﬁed by the disproportionate contribution
from low and middle-income countries to cancer mortality statistics,
with the true magnitude of the problem almost certainly underestimated due to the inaccessibility of diagnostic and treatment
pathways to most patients [17–19].

Discrepancies in AML outcomes related to NBF are well
documented even within countries with high gross national
incomes [20–27], with a recent Surveillance, Epidemiology, and
End Results (SEER)-based study demonstrating a concerning
widening of the survival gap between Black and White patients
in the USA [28]. Patients with signiﬁcant NBF and associated multimorbidity [16], and those from certain ethnic groups remain
under-represented in clinical trials [29], with these variables not
featuring in any prognostic model for AML. For strategies in
personalized medicine to be truly effective, the possibility of
ethnicity-associated variation in outcomes, even with similar
genetic drivers of disease and therapy [28] requires systematic
investigation, and the term “supportive care” requires redeﬁnition
to include assistance with outcome-affecting NBF.
Here, we have used four real patient exemplars to review NBF
that can interfere with the delivery of optimal AML treatment in
different healthcare systems. The use of the case-based format
that clinicians are familiar with, helps illustrate the extent of the
challenge in a more transparent manner than is possible with
quantitative analyses. Overcoming the difﬁculties in each narrative, all unrelated to the biology of the disease, requires signiﬁcant
longer-term ﬁnancial and human investment, along with fundamental changes to the deﬁnition of well-being and expectation,
not only from health policymakers and physicians, but also from
patients and the public.
PATIENT 1
A 34-year-old, previously healthy Nigerian Ph.D. student, resident
in New Zealand on a Student Visa with his wife and 1-year-old
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child, presented with pancytopenia and blast cells in his blood
ﬁlm. Physical examination was unremarkable. Bone marrow biopsy
showed a myeloid maturation arrest, with 82% monoblasts
expressing CD45, CD64, CD33, CD4, CD56, and HLA-DR, conﬁrming
a diagnosis of AML with monocytoid differentiation. Marrow
cytogenetic analysis showed a normal 46, XY karyotype. Mutation
analysis of PCR-ampliﬁed bone marrow DNA was negative for
NPM1 and FLT3 gene variants, including FLT3 internal tandem
duplications (ITD) and tyrosine kinase domain mutations.
TREATMENT OPTIONS
Based on the initial work-up, this patient had “intermediate-risk
AML” [30–32]. With anthracycline and cytarabine-based induction
chemotherapy, he had a 60–80% chance of achieving morphological remission, but with a high relapse-risk and 5-year survival
of approximately 50% [30–32]. The risk of relapse can be reduced
through the pre-emptive use of allogeneic stem cell transplantation (alloSCT) in ﬁrst complete remission (CR1), since a donorversus-no donor comparison confers a survival advantage with
alloSCT in younger patients [33]. However, the ﬁscal implications
of alloSCT and potential for toxicity, including death, mean that
the allocation of alloSCT in CR1 should be risk-adapted and only
offered to those with a higher predicted relapse-risk [34, 35].
Strategies for further risk-stratifying “intermediate-risk” AML
patients include the use of targeted next-generation sequencing
(NGS) in diagnostic specimens to detect gene variants associated
with relapse, or the quantiﬁcation of MRD at different stages of
treatment using genetic markers or multi-parametric ﬂowcytometry [36–38]. In this context, it is important to acknowledge
challenges to the standardization, quantiﬁcation, and interpretation of genomic and ﬂow-cytometry MRD that may limit the
widespread adoption of MRD assessment as a prognostic tool [39].
Prospective randomized conﬁrmation of the reduction in relapserisk through post-remission intensiﬁcation or alloSCT, based on
mutational load and genomic proﬁle at diagnosis, or MRD status,
is required before MRD-adapted therapy becomes standard
practice. In the absence of MRD measurements, validated scoring
systems [40] and comorbidity [41] can be used to aid informed
decision-making on alloSCT.
MANAGEMENT AND OUTCOME
As a non-citizen, the patient did not automatically qualify for
publicly funded AML treatment in New Zealand. He considered
the low likelihood that he would receive appropriate treatment if
he returned to his native Southern Nigeria, where he understood
neither induction chemotherapy nor alloSCT was available.
Therefore, he applied for leukemia treatment funding under his
healthcare insurance policy in New Zealand and received approval
for a maximum of four chemotherapy cycles, speciﬁcally excluding
costs of alloSCT. Consequently, the use of molecular genomic riskbased or MRD-based allocation to alloSCT was not an option for
this patient, whose treatment was determined solely by his
insurance policy funding limitation that excluded alloSCT at
any time.
He started intensive induction therapy with daunorubicin
(60 mg/m2 on days 1, 3, and 5) and cytarabine (100 mg/m2)
administered 12 hourly for 10 days (DA(60) 3+10) [14]. Bone
marrow biopsy on day 29 of treatment following count recovery
showed blasts of 8% indicating partial remission. Based on this
level of cytoreduction, there would be no obvious beneﬁt with
alloSCT, particularly if CR is achieved after another cycle of
induction therapy [40, 42]. He proceeded to his second cycle of
treatment with 50 mg/m2 of daunorubicin on days 1, 3, and 5, and
8 days of cytarabine (100 mg/m2) administered 12 h apart (D(50)A
3+8) with a plan for consolidation with two cycles of high-dose
cytarabine (3 g/m2), followed by an expectant observational

strategy. Importantly, his visa status did not support publicfunded remission re-induction followed by alloSCT in the event of
relapse.
COMMENTS
The World Health Organisation (WHO) recognizes healthcare
coverage as a global problem for the increasing number of
international migrants and refugees in their draft global action
plan, 2019-2023 [43]. In New Zealand, a refugee or “protected
person” is covered by publicly funded health and disability
services, but a full fee-paying student on a Student Visa is not
eligible for state-funded healthcare and is required to hold
healthcare insurance. The patient is thus responsible for healthcare costs that are not covered by insurance.
If insurance for healthcare costs is limited or absent, the
personal responsibility to fund accumulating costs can be stressful
for the patient and become a challenge for the hospital’s Eligibility
Team. Life-saving interventions are provided regardless of a
patient’s ability or willingness to pay, but cost recovery remains an
expectation. Elective interventions to mitigate relapse-risk, for
example, are not offered as publicly funded options. It is therefore
important to indicate the costs of therapy to the patient early on
during discussions regarding treatment. Despite language barriers
that often compound the situation, clarity of communication is
vital to emphasize the ﬁnancial investment required to provide
care that meets the country’s expected quality standard and is
considered essential and life-saving. Permanent or temporary
migrants, particularly fee-paying students, by the mere nature of
their experiences are amongst those who would understand the
nuances associated with the costs of treatment. If they originate
from parts of the world where care is less than optimal, they could
end up feeling victims of the system in the country of residence,
as well as the place they consider “home”.
PATIENT 2
A 30-year-old self-employed man, recently married, and with an
income of less than US$ 285 per month presented with
breathlessness, fever and leg pain to the hospital Emergency
Department in Ludhiana, India. He had low hemoglobin (62 g/L),
white cell count of 68.3 × 109/L (predominantly blasts), and a
platelet count of 259 ×109/L. Coagulation screen, renal and liver
function were normal. The bone marrow contained >80% blasts
expressing CD34, HLA-DR, CD33, CD13, CD11b, and CD117
indicating a diagnosis of AML. Cytogenetic analysis was normal,
and multiplex polymerase chain reaction did not detect the fusion
gene re-arrangements CBFβ-MYH11, RUNX1-RUNX1T1, PML-RARA,
BCR-AB1, or mutations in NPM1, FLT3, c-KIT, or CEBPA. The
estimated costs for the diagnostic work-up including genetic
testing was estimated at US$ 430.
TREATMENT OPTIONS
As with the previous case, this patient had intermediate-risk AML,
but possibly with a greater relapse-risk on account of the higher
white count [40]. He would be a candidate for standard induction
therapy with an anthracycline and cytarabine backbone with postremission therapeutic options assessed either through additional
NGS or MRD studies. However, the Indian healthcare system is
mainly reliant on patient-funded therapy and supportive care,
making consideration of cost the starting-point of the treatment
algorithm. For this patient, the cost of induction therapy was
estimated to be between US$ 7150 and 11,450. For managing
persistent fever and blood product support, the daily costs
including hospital charges would be between US$ 214 and 285.
The high incidence of invasive fungal infections, with the
likelihood of requiring liposomal amphotericin, escalates the
Blood Cancer Journal (2021)11:141
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cumulative cost by at least 25% [44]. If remission is achieved,
consolidation therapy with 3 cycles of cytarabine (3 g/m2) is
estimated at US$ 20,200 in total, and alloSCT is expected to cost
an additional US$ 14,300–21,450. The expected incidence of
induction deaths is 25% [45]. The patient was offered induction
treatment with daunorubicin (60 mg/m2/day for 3 days) and
infusional cytarabine (100 mg/m2/day) for 7 days (DA(60) 3+7)
[46] and subsequent consideration of alloSCT in remission,
pending identiﬁcation of an HLA-matched family donor and
additional funding.
MANAGEMENT AND OUTCOME
Following treatment with “DA(60) 3+7”, he required antibiotics for
transient febrile neutropenia. On day +15, his white cell count
increased to 9.8 × 109/L with >90% of blasts. The kinetics of
disease re-emergence with no reduction in the proportion of
circulating blasts suggested primary refractory disease and the
likely futility of a repeating induction treatment [42]. Treatmentintensiﬁcation with ﬂudarabine-based chemotherapy (FLAG-Ida)
followed by consolidation with alloSCT was considered pending
tissue-typing.
The re-calculated costs for FLAG-Ida alone, or in sequence with
alloSCT in aplasia was estimated between US$ 14,300 and 35,714.
Having to source this amount of money, for an estimated 20%
chance of cure with the proposed treatment, was not an
acceptable trade-off for the patient or his family. He expressed a
desire to try an alternative, affordable treatment to prolong life
and was offered treatment with subcutaneous azacitidine.
However, he defaulted from follow-up less than 4 weeks into
the diagnosis.
COMMENTS
In the Indian healthcare system, discussions around estimated
treatment expenses and outcomes, based on biological parameters relevant to AML are critical before therapy, as physicians
and patients attempt to balance the affordability of treatment
with expected survival. This balance, a key determinant of
treatment decisions becomes the proxy for cost-effectiveness,
individual to each patient’s ﬁnancial circumstances.
With a population approaching 1.4 billion, the Total Health
Expenditure (THE) for India is estimated at US$ 70 billion (3.84% of
GDP and US$ 54.40 per capita). The healthcare system is
characterized by the co-existence of public and private health
centers, poor public health infrastructure, high health care costs,
and low insurance coverage [47]. The proportional contribution of
patient-funded, out-of-pocket expenditure (OOPE) to THE is 60.6%,
with smaller contributions from the government (22.8%), insurance (4.8%) and external donors including non-government
organizations (11.8%) [47, 48]. Typical forms of distress ﬁnancing
to deal with the increased OOPE on health care include current
income, savings, mortgaging and selling of assets, loans from
moneylenders and ﬁnancial institutions, and reduction in consumption expenditure [49, 50]. The adverse consequences of
borrowing and selling assets to meet OOPE have signiﬁcant shortterm and longer-term consequences [51, 52]. Thus, the median
age of AML patients treated in large centers in India is as low as 40
years, with less than a third of patients opting for induction
chemotherapy, and standard-of-care treatments offered only to
those with the potential to complete therapy [45].
PATIENT 3
A 65-year-old African-American male living in the urban community in Detroit, USA, presented to an “outside” hospital with an
infected right toe in January 2020 and a leucoerythroblastic blood
ﬁlm. He had retired 5 years previously, lived with his mother, and
Blood Cancer Journal (2021)11:141

had an ECOG performance status of 2. Past medical history was
signiﬁcant for morbid obesity and obstructive sleep apnea
requiring non-invasive ventilation, hypertension, non-insulindependent diabetes mellitus, and gout. Due to persisting infection
and risk of overwhelming sepsis, he underwent amputation of the
toe, following which he developed renal failure. Intravenous
hydration caused circulatory overload and respiratory failure. Due
to worsening leukocytosis, bone marrow examination was undertaken and AML was identiﬁed. He was transferred to a specialist
unit with low hemoglobin (68 g/L) and platelet count (37 × 109/L),
with a white cell count of 79.3 × 109/L and excess monoblasts and
promonocytes. Repeat marrow examination conﬁrmed monoblastic AML by morphology and immunophenotyping. Results of
cytogenetic analysis received after the patient had started
leukemia therapy identiﬁed inv [16] (p13.1q22), conﬁrmed by
interphase FISH in 85% of cells. NGS detected a low-level variant in
NRAS and KIT.
TREATMENT OPTIONS
Based on age, patients with AML often end up being categorized
as either “ﬁt” or “unﬁt” to help determine the intensity of
induction chemotherapy [53]. The presence of inv [16] is a “good
risk” cytogenetic abnormality in AML, predicting a good response
to intensive chemotherapy, particularly in patients younger than
60 years [30–32]. While remission rates in older patients are
comparable, the relapse-risk is higher, with lower overall survival
[54]. The addition of Mylotarg/gemtuzumab ozogamicin (GO), a
humanized anti-CD33 monoclonal IgG4 antibody conjugate with
calicheamicin to chemotherapy has been shown to associate with
superior event-free and overall survival in AML [55–58]. Younger
patients with “good risk” cytogenetic abnormalities are thought to
derive particular beneﬁt [55, 56], but the low incidence of this
genetic subset in older patients makes the risk-beneﬁt analysis of
GO in patients ≥60 years of age with inv [16] AML less clear
[57, 59]. Nevertheless, the use of GO with intensive chemotherapy
is considered the standard for disease characterized by this
chromosomal lesion [53], and the timely turnaround of genetic
results is critical to inform optimal therapy with licensed targeted
drugs or clinical trial participation.
Despite conﬂicting data, the presence of molecular genetic
lesions, including concomitant mutations in KIT and NRAS may
inﬂuence relapse following chemotherapy [60–63]. Whether
intensifying therapy through alloSCT in CR1 in disease with a
low burden of mutant alleles will improve outcomes, is unclear,
but the measurement of fusion gene (CBFB-MYH11) transcripts as a
marker of MRD, at pre-deﬁned time-points during chemotherapy
can be used to identify those at higher risk of relapse and guide
therapeutic interventions including alloSCT [64]. Whether serial
MRD monitoring to guide pre-emptive therapy will improve
prognosis over offering treating at the point of hematological
relapse, and outweigh the organizational and technical investment for MRD measurement and periods of potential inconvenience and anxiety to patients, is being investigated in the UK
AML-17 trial for younger patients [14].
MANAGEMENT AND OUTCOME
Based on frailty at the time of inter-hospital transfer and multimorbidity pre-dating AML diagnosis, it was doubtful whether the
patient would tolerate intensive chemotherapy. By optimizing
ﬂuid management, his organ function returned to baseline; based
on leucocytosis mandating urgent treatment and normal cardiac
imaging, he was offered intensive induction chemotherapy before
the cytogenetic results were available. He consented to participate
in phase II/III clinical trial investigating an experimental drug,
administered with “DA(60) 3+7”. Randomized to the experimental
arm, his tolerance of induction treatment was good. The day 14
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bone marrow specimen identiﬁed resistant blasts (19%) but
represented a >50% reduction in disease-burden over the
diagnostic biopsy. Complications following re-induction therapy
included culture negative neutropenic fever and respiratory
distress, but invasive ventilation was not required. Coinciding
with blood count recovery and attainment of CR, he became
afebrile and oxygen-independent, although required transfer to
an inpatient rehabilitation facility due to deterioration in mobility,
functional and psychological status.
In view of the higher relapse-risk due to age and concurrent
mutations in KIT and NRAS [63], the option of unrelated donor
alloSCT as a post-remission strategy was subsequently discussed
with the patient. He declined due to concerns regarding physical
and psychological tolerance of treatment and suboptimal family
support. Since the addition of GO was not permitted as per trial
protocol, he was scheduled to continue on study for a total of
three consolidation cycles with the investigational drug and highdose cytarabine (2 g/m2), with observational follow-up. The
alternative strategy of withdrawing him from the trial and treating
him with GO-containing consolidation was not pursued. Since
multi-morbidity and psychological frailty excluded alloSCT as a
viable pre-emptive management strategy, MRD assessment
through serial quantiﬁcation of CBF-MYH11 transcripts was not
undertaken.
COMMENTS
Rapid changes in urbanization can negatively impact the
economic and social structures of inner-city communities,
adversely affecting health and quality of life [65]. Currently, over
half of the world’s population lives in urban areas, and this is
increasing markedly year-on-year, notably in less economically
developed regions of the world [66]. Conversely, in more
economically developed countries, the population decrease in
previously afﬂuent urban industrial areas has worsened the living
conditions of those left behind [67, 68]. With a population of 1.85
million in 1950, Detroit was America’s ﬁfth-largest city, but on
account of human migration, was ranked closer to 20th by 2016,
with a residual population of under a million. Similar to many
midwestern and eastern cities in the USA, Detroit lost middle class
and well-to-do families to its suburbs, taking away both people
and jobs. The resulting restrictive business practices contributed
to overcrowding and physical deterioration of neighborhoods
within the city, similar to the predicament in other cities [66–69].
Soon, the multi-morbidity associated with deprivation that
extends beyond measures of socioeconomic status, begins to
deﬁne the neighborhood and interferes with the care of
individuals, particularly those under the age of 70 years [70–72].
PATIENT 4
A 56-year-old man presented to a hospital in Dundee, Scotland,
UK with a brief history of progressive shortness of breath. Blood
work demonstrated: hemoglobin 54 g/L, white cell count of 2.0 ×
109/L, neutrophil count of 0.4 × 109/L, and platelet count of 52 ×
109/L, with normal coagulation screen. Bone marrow was
inﬁltrated with blasts (72%) expressing CD33, CD13, CD117, and
myeloperoxidase, indicating a diagnosis of AML. Cytogenetic
analysis was normal and molecular analysis identiﬁed mutant
NPM-1 and wild-type FLT3. Renal and liver function were normal,
while comorbidity included mild chronic obstructive airways
disease and previous history of alcohol-dependence syndrome.
TREATMENT OPTIONS
Approximately 30% of patients with AML have a detectable
mutation in nucleophosmin-1 (NPM-1) [73]. The frequency is
higher in cytogenetically normal disease, and the prognosis with

standard intensive chemotherapy is good in younger patients and
those without a co-existing high FLT3-ITD burden [74, 75]. The
ﬁdelity of mutant NPM-1 in most patients makes it a useful marker
to quantify molecular MRD responses at pre-deﬁned time-points
following therapy to identify patients in CR1 who require
treatment intensiﬁcation for cure [76, 77]. More recently, lowerintensity protocols combining venetoclax with low-dose cytarabine or azacitidine [78, 79] have resulted in durable responses in
NPM-1mutant AML even in patients with molecular persistence or
relapse following standard intensive chemotherapy [79]. On-going
clinical trials aim to establish whether venetoclax-containing
lower-intensity therapy should become the standard approach
for all patients with NPM-1mutant FLT3wt AML.
MANAGEMENT AND OUTCOME
This patient was offered intensive induction therapy with “DA(60)
3+10” [14]. Although he had no signiﬁcant problems with his
physical health, he was known to the psychiatric services since the
age of 11 years, when he was evaluated for encopresis. In his 20 s,
he was diagnosed with depressive neurosis and a schizoid
personality disorder, revised to an “obsessional disorder”. He
had been receiving help with anxiety management but defaulted
from follow-up. He lived alone, was unemployed, and received
social support from his daughter and a local priest. Over a 10-year
period pre-dating the diagnosis of AML, he had contacted the
emergency health services over 100 times for non-speciﬁc
symptoms. He tended to self-discharge after hospitalization;
eventually, his symptoms were attributed to somatization.
Despite the apparent understanding of the poor prognosis
associated with untreated AML (conﬁrmed by liaison psychiatry)
the patient declined intensive chemotherapy in favor of supportive care and was discharged from the hospital. As an outpatient,
he received treatment with subcutaneous low-dose cytarabine at
a dose of 40 mg/day for 10 days. At the end of cycle 1, the blood
count normalized to suggest remission. The patient expressed a
desire to receive intensive chemotherapy, “to be able to remain
alive”, thus demonstrating awareness of the non-curative effects
of low-dose cytarabine. Following discussions involving the
patient, liaison psychiatry, the patient’s daughter, priest, and
family practitioner, a Hickman line was inserted to deliver
intravenous cytarabine (1 g/m2 12 hourly on alternate days, for a
total of 6 doses). As the Hickman line was being accessed to
administer the ﬁrst dose of cytarabine, he decided against
proceeding with any form of treatment. Disease relapse followed
and the patient died within 6 months.
COMMENTS
Patients receiving a cancer diagnosis often experience a reactive
deterioration in mental health [80]. However, as exempliﬁed by
this patient, poor mental health pre-dating the diagnosis of AML
can add to the challenge of delivering optimal anti-leukemic
therapy despite access to the publicly funded National Health
Service Scotland. Socioeconomically, Dundee is a relatively
deprived area of the country [81, 82], with around 40% of
neighborhoods falling into the 20% most deprived areas in
Scotland. Indeed, a signiﬁcant proportion of the local population
resides in areas with high death rates due to cancer, cardiovascular causes, drugs, and alcohol, and are three times more likely
than those living in afﬂuent areas to have below-average mental
well-being. The cancer incidence and mortality rates in Scotland’s
most deprived areas are, respectively, 32% and 74% higher than
the least deprived areas, with a trend toward increasing mortality
from the least deprived to most deprived areas in patients with
leukemias [83]. Clearly, as well as physical health, poor mental
health, and socioeconomic deprivation [16, 84, 85], both of which
are associated with poor health service engagement and poor
Blood Cancer Journal (2021)11:141
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cancer outcomes, require targeting with more support than is
currently provided.
DISCUSSION
The cases discussed here serve as a stark reminder of the
challenges to be addressed proactively if AML patients worldwide
are to beneﬁt from improved diagnostic and disease-management
strategies. Socioeconomic deprivation lies at the crux of many
disparities, whether it be drug costs and the ﬁnancing of
supportive care, evident in the patient exemplars from India and
New Zealand, or the physical or mental consequences of longterm social deprivation in the patient narratives from the USA and
UK. Regrettably, there are few immediate solutions for optimizing
the care of these patients, a fact that may seem incredulous to
clinicians inexperienced in managing patients from deprived
backgrounds: indeed, it would be easy to overlook subconsciously,
the absence of interchangeability between the provision of
disease-centered care and patient or people-centric management.
The importance of implementing proposals aiming to reduce
disparities in care therefore cannot be overemphasized.
Initiatives that could improve access to drugs include promoting value-based control of drug pricing, standardizing drug costs
to national gross domestic product, and practice guidelines based
on the best level of evidence [86]. For example, in the UK, health
technology appraisal of new drugs is undertaken to determine
“value-for-money” before the single-payer health system decides
to fund the drug. Drug costs can also be reduced through the
administration of lower drug doses, provided the efﬁcacy of
therapy is not compromised: in chronic myeloid leukemia (CML),
many patients with excellent disease control can be safely
maintained on a de-escalated dose of tyrosine kinase inhibitor
[87]. The disease kinetics in AML requires a different approach,
with an investigation of the pharmacogenomic determinants of
drug metabolism and levels, or multi-drug schedules that permit
dose-reductions through pharmacokinetic interactions: as an
example, in combination with anti-fungal azole drugs, a considerably lower dose of venetoclax can be administered thereby
reducing drug costs [88]. The affordability of leukemic drugs can
also be improved through changes to the duration and scope of
patent protection, or implementation of differential pricing
structures [86]. It would however be naïve to underestimate the
complexity of the challenges involved in getting agreement from
different organizations involved in policy-making, and as “social
advocates”, hemato-oncologists have an important role in shaping
decisions.
Relevant to the costs of supportive care with blood products
and anti-microbial therapy in newly diagnosed patients and
during post-treatment aplasia, high-income countries have
strategies that support patients through this phase of treatment.
In many low and middle-income regions, there remains a lack of
diagnostic capability and treatment centers with infrastructure
capable of providing high-intensity supportive care [89]. Overcoming this deﬁcit requires both national and international
initiatives that create a network of high-quality centers per head
of population that are accessible, accountable and offer standardized care at affordable or subsidized costs. The Ayushman Bharat
National Health Protection Mission is India is one such ambitious
project aiming to reduce economic disparities in healthcare
including cancer treatments [90].
One possible way of adapting the governance and delivery of
care to communities is through decentralizing health to local or
regional governments [89], and maintaining incidence and
outcomes statistics for the devolved regions so that the need
for additional resource can be identiﬁed. The Cancer Quality
Performance Indicators (QPI) in Scotland (https://www.isdscotland.
org/Health-Topics/Quality-Indicators/Cancer-QPI/) exemplify a
national governance framework that supports and measures the
Blood Cancer Journal (2021)11:141

performance of regional cancer centers against a pre-deﬁned
’standard of care’ target in cancers including AML, aiming to
improve patient experience and survival whilst “reducing variance
and ensuring safe, effective and person-centered cancer care”.
Using survival as the surrogate for measuring “performance”
however has the potential to be misleading due to the rarity and
heterogeneous nature of AML, but data on treatment-type and
early mortality, linked to patient demographics can help develop
an understanding of disparities in therapy and unmet need. For
example, publically available acute leukemia data on Scottish
patients between 2014 and 2017 [91] have demonstrated areas for
improvement: comprehensive diagnostic work-up was not undertaken in >25% of patients treated with curative intent, and access
to clinical studies requires review, as <60% of patients received
potentially curative treatment as trial participants. The QPI
program, including the rationale for setting performance targets
is not perfect and currently enables a comparison of regional
rather than socioeconomic status-associated variation in healthcare, but the evolving model for egalitarian care that it provides
should be lauded and adapted in other regions. Further steps
towards providing equity of care include reviewing the two-tier
framework that supports healthcare budgetary constraints, for
example, in migrants faced with unexpected illness in New
Zealand, and expanding the coverage of existing insurance
schemes such as Medicaid, offering healthcare to the most
deprived segments of society [92]. These initiatives should run in
parallel with community educational programs that improve
awareness of the importance of early diagnosis and treatment,
common to all cancers.
When the affordability of a drug, or treatment costs are not a
major barrier to therapy, the consequences of established physical
or mental comorbidity, or behavioral issues that reﬂect protracted
social deprivation become obstacles, as seen in the patients from
the USA and UK. In patients unwilling to engage regularly with the
healthcare system, interventions akin to those trialed with variable
levels of success in public health initiatives tackling alcoholism
[93], smoking [94], or hepatitis C therapy [95] require consideration: the use of text-message or speciﬁc app-based interventions
or increased involvement of community-based allied healthcare
professionals may optimize treatment compliance, an issue of
particular importance with the advent of newer, oral drugs that
can increase patient empowerment, and yet be paradoxically less
desirable in some patients. The physical consequences of
deprivation that interfere with the decision regarding intensive
genotoxic therapy of AML are often irreversible. However, the
identiﬁcation of newer drugs with acceptable toxicity proﬁles may
offer suitable alternatives to these patients. Prevention of physical
comorbidities associated with socioeconomically deprived environments requires a longer-term approach that includes regeneration schemes [96] and research on environmental enrichment [97]
as a means of reversing attitudes and health. Initiatives that
improve access to services and social care, support healthier
lifestyles, reducing worklessness, and improve social mobility are
all longer-term strategies to improve general health and wellbeing within a community.
It is perhaps utopian to expect an elimination of disparities in
AML care, but the experience with the distribution of antiretroviral medication for human immunodeﬁciency virus infection
[17], and the global collaboration resulting in comparable
outcomes in acute promyelocytic leukemia in lower and highincome countries [98] are reasons for cautious optimism about the
ability to reduce disparities, provided the desire for change is
indeed genuine. Traditionally, risk-stratiﬁcation that is used to
inform therapeutic intervention in AML has been founded on the
measurement of biological parameters. It is now time for us to
consciously acknowledge socioeconomic and anthropogeographical confounders of outcomes, be courageous in expanding
patient participation in clinical trials, and include measurement of
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NBF to improve the accuracy of prognostication and the
assessment of disease impact on societies.
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